← Back to Directory

Carnosine Eye Drops

N-acetylcarnosine eye drops, NAC eye drops, Can-C

Visual ViewRaw Data

Meta Information

ID:carnosine-eye-drops
Name:Carnosine Eye Drops
Schema Version:1.5

Alternate Names

  • N-acetylcarnosine eye drops
  • NAC eye drops
  • Can-C

Active Compound

L-carnosine

Intervention Type

therapeutic_agent

Delivery

Route:
eye
Scope:
  • local

Regulatory Status

  • us:otc_drug
  • us:cosmetic

Indication

Focus:
healthspan
Description:
Aimed at mitigating age-related decline in eye health, particularly lens clouding (cataracts) and general oxidative stress.

Typical Protocol

  • Apply 1-2 drops of a 1% N-acetylcarnosine solution to each eye, two times per day.

Expected Cost Mean

Low Cost:
20
High Cost:
40
Cost Type:
monthly
Description:
Cost for one or two bottles for a month's supply; not insurance covered.

Summary

Carnosine is an antioxidant and anti-glycating dipeptide naturally present in tissues. In the eye, it is proposed to protect the lens proteins from cross-linking and oxidation, which are key drivers of age-related cataract formation. N-acetylcarnosine (NAC) is a more stable form used in eye drops that is converted to carnosine within the eye, potentially slowing the progression of lens opacification.

Purpose

Antioxidant eye drops to combat age-related lens clouding and oxidative stress.

Card Summary

Topical antioxidant eye drops intended to slow the progression of age-related cataracts by reducing glycation and oxidative damage in the lens.

Drug Class

null

Drugs In Class

Empty Array

Impact

Score:
3.5
Justification:
Limited human data suggests potential for slowing cataract progression, but lacks robust validation.

Evidence

Grade:
B
Score:
4.5
Justification:
Based on small human trials, primarily from one research group, lacking large-scale replication.

Safety

Score:
2.5
Justification:
Topical application with minimal systemic absorption; main side effect is temporary eye irritation.

Flags

  • Primary side effect is temporary stinging or burning upon application.
  • Efficacy for reversing existing cataracts is not supported by strong evidence.
  • Should not be used as a substitute for professional ophthalmological care or surgery.
  • Ensure the product is sterile and from a reputable manufacturer.

Verdict

A low-risk, experimental approach for potentially slowing early-stage cataract progression.

Qualifier

route: eye, scope: local, focused on healthspan

Created

2026-05-07T02:00:22.354457Z

Ai Model

Gemini 2.5 Pro (High)